| FoxO3 regulates neural stem cell homeostasis VM Renault, VA Rafalski, AA Morgan, DAM Salih, JO Brett, AE Webb, ... Cell stem cell 5 (5), 527-539, 2009 | 624 | 2009 |
| Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma LA Johnson, J Scholler, T Ohkuri, A Kosaka, PR Patel, SE McGettigan, ... Science translational medicine 7 (275), 275ra22-275ra22, 2015 | 491 | 2015 |
| Directional DNA methylation changes and complex intermediate states accompany lineage specificity in the adult hematopoietic compartment E Hodges, A Molaro, CO Dos Santos, P Thekkat, Q Song, PJ Uren, J Park, ... Molecular cell 44 (1), 17-28, 2011 | 335 | 2011 |
| Exome sequencing and disease-network analysis of a single family implicate a mutation in KIF1A in hereditary spastic paraparesis Y Erlich, S Edvardson, E Hodges, S Zenvirt, P Thekkat, A Shaag, T Dor, ... Genome research 21 (5), 658-664, 2011 | 208 | 2011 |
| The pro-longevity gene FoxO3 is a direct target of the p53 tumor suppressor VM Renault, PU Thekkat, KL Hoang, JL White, CA Brady, ... Oncogene 30 (29), 3207-3221, 2011 | 146 | 2011 |
| Dicer-2 processes diverse viral RNA species LR Sabin, Q Zheng, P Thekkat, J Yang, GJ Hannon, BD Gregory, M Tudor, ... PloS one 8 (2), e55458, 2013 | 125 | 2013 |
| Characterization of INCB086550: a potent and novel small-molecule PD-L1 inhibitor HK Koblish, L Wu, LCS Wang, PCC Liu, R Wynn, J Rios-Doria, S Spitz, ... Cancer Discovery 12 (6), 1482-1499, 2022 | 56 | 2022 |
| The novel bromodomain and extraterminal domain inhibitor INCB054329 induces vulnerabilities in myeloma cells that inform rational combination strategies MC Stubbs, TC Burn, R Sparks, T Maduskuie, S Diamond, M Rupar, ... Clinical Cancer Research 25 (1), 300-311, 2019 | 48 | 2019 |
| Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med. 2015; 7 (275): 275ra22 LA Johnson, J Scholler, T Ohkuri, A Kosaka, PR Patel, SE McGettigan, ... Epub 2015/02/20. doi: 10.1126/scitranslmed. aaa4963. PubMed PMID: 25696001, 0 | 23 | |
| Characterization of INCB00928, a potent and selective ALK2 inhibitor for the treatment of anemia Y Chen, MC Stubbs, M Pusey, X Wen, RJ Collins, K Kapilashrami, ... Blood 136, 52, 2020 | 6 | 2020 |
| Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors H Wang, PN Carlsen, T Huang, Y Li, LIN Luping, QI Chao, PU THEKKAT, ... | 4 | 2021 |
| Novel small-molecule antagonists of the PD-1/PD-L1 axis that mediate cell surface PD-L1 dimerization and internalization PCC Liu, R Wynn, L Wu, A Volgina, N Zolotarjova, L Lin, P Thekkat, ... Cancer Research 79 (13_Supplement), 4483-4483, 2019 | 2 | 2019 |
| Pre-clinical validation of a humanized anti-EGFR variant III chimeric antigen receptor and phase I trial of CART-EGFRvIII in glioblastoma LA Johnson, J Scholler, T Ohkuri, A Kosaka, PR Patel, SE McGettigan, ... Journal for ImmunoTherapy of Cancer 2, 1-1, 2014 | 2 | 2014 |
| 232 INCB090244, a potent small molecule that inhibits the PD-L1/PD-1 axis and functions similarly to PD-L1 antibodies J Rios-Doria, A Volgina, P Gokhale, H Liu, C Stevens, N Zolotarjova, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 1 | 2021 |
| Abstract LB157: Discovery and characterization of INCB106385: a novel A2A/A2B adenosine receptor antagonist, as a cancer immunotherapy H Wang, A Alexandra, M Hansbury, J Mason, J Harris, C Stevens, ... Cancer Research 81 (13_Supplement), LB157-LB157, 2021 | 1 | 2021 |
| The role of HPK1 in the regulation of T cell function and anti-tumor immune activity Y Chen, J Rios-Doria, M Pusey, K Lasky, M Ye, P Thekkat, K Gallagher, ... Cancer Research 80 (16_Supplement), 4513-4513, 2020 | 1 | 2020 |
| Validation of a humanized anti-EGFR variant III chimeric antigen receptor for a phase I trial of CART-EGFRvIII in glioblastoma J Brogdon, A Loew, P Thekkat, N Idamakanti, B Engels, R Singh, T Ezell, ... Science Translational Medicine, 2015 | 1 | 2015 |
| Transcriptional regulation of glucose-6-phosphate dehydrogenase (G6PDH) by glucose PU Thekkat | 1 | 2007 |
| Terapia combinada que comprende inhibidores de a2a/a2b y pd-1/pd-l1. T Huang, W Zhu, L Wu, W Yao, C Qi, PN Carlsen, Y Li, H Wang, L Lin, ... | | 2023 |
| A biologic screen to evaluate potential toxicity of chimeric antigen receptor modified T cells against primary normal human tissues AP Cogdill, A Boesteanu, K Haines, J Fraietta, J Scholler, A Loew, ... CANCER IMMUNOLOGY RESEARCH 3 (10), 2015 | | 2015 |
